Clinical trials: Genital Neoplasm, Female
HER2-positive Solid Tumors, HER2-positive Breast Cancer
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
A first-in-human study using BDC-1001 as a single agent and in combination with nivolumab in HER2 expressing advanced malignancies
- Conditions
- HER2-positive Solid Tumors, HER2-positive Breast Cancer, HER2-positive Colorectal Cancer, HER2-positive Gastroesophageal Cancer
- Trial name
- NCT04278144
- Testing
- BDC-1001, Nivolumab
- Where
- 21 sites in United States, France and 2 more
- Volunteers
- 175 people
- Sponsor
- Bolt Biotherapeutics, Inc.
Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase III trial studies how well letrozole with or without paclitaxel and carboplatin works in treating patients with stage II-IV low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum.
- Conditions
- Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma, Primary Peritoneal Low Grade Serous Adenocarcinoma, Stage II Fallopian Tube Cancer AJCC v8
- Trial name
- NCT04095364
- Testing
- Biopsy Procedure, Biospecimen Collection, Carboplatin
- Where
- 909 sites in United States, Canada and 4 more
- Volunteers
- 450 people
- Sponsor
- NRG Oncology
Ovarian Cancer
Radiolabeled Folic Acid and Imaging to Detect Ovarian Cancer
RATIONALE: Diagnostic procedures using the drug radiolabeled folic acid and imaging may be effective in detecting ovarian cancer.
- Trial name
- NCT00003763
- Testing
- radionuclide imaging, indium In 111 folic acid
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Endocyte
Stage III Ovarian Carcinoma, Stage IV Ovarian Carcinoma
Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas
This is a double-blind study in which approximately 99 study patients will be randomized in a 2:1 ratio to receive either AVOVA-1 or MC.
- Conditions
- Stage III Ovarian Carcinoma, Stage IV Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
- Trial name
- NCT02033616
- Testing
- AVOVA-1, MC
- Where
- 6 sites in United States
- Volunteers
- 99 people
- Sponsor
- Aivita Biomedical, Inc.
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)
This is a randomized, open label, multicenter trial to evaluate the safety, dosing, efficacy and biological activity of intraperitoneal IMNN-001 plus NACT compared to NACT alone.
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- OVATION 2 (NCT03393884)
- Testing
- IMNN-001, Carboplatin, Paclitaxel
- Where
- 21 sites in United States, Canada
- Volunteers
- 130 people
- Sponsor
- Imunon
Ovarian Serous Adenocarcinoma, Undifferentiated Carcinoma of Ovary
Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity
This study is a clinical study aiming at establishing immunological assays for the qualitative and quantitative evaluation of WT-1, Survivin and HPV16 E7-specific immune responses in cancer patients.
- Conditions
- Ovarian Serous Adenocarcinoma, Undifferentiated Carcinoma of Ovary, Cervical Cancer, Cervical Intraepithelial Neoplasia, Grade 3
- Trial name
- NCT02016833
- Testing
- Blood Sampling
- Where
- Australia
- Volunteers
- 15 people
- Sponsor
- PX Biosolutions
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms
AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer
This is a multi-center, open-label phase 1 dose escalation trial that uses a modified 3+3 design to identify a recommended phase 2 dose (RP2D) of AB-1015 cell product.
- Conditions
- Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms
- Trial name
- NCT05617755
- Testing
- AB-1015
- Where
- 8 sites in United States
- Volunteers
- 19 people
- Sponsor
- Arsenal Biosciences, Inc.
Cognitive Side Effects of Cancer Therapy, Malignant Ovarian Epithelial Tumor
Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy
This clinical trial is studying changes in brain function in patients with stage I, stage II, stage III, or stage IV ovarian, primary peritoneal, or fallopian tube cancer who are receiving chemotherapy.
- Conditions
- Cognitive Side Effects of Cancer Therapy, Malignant Ovarian Epithelial Tumor, Ovarian Brenner Tumor, Ovarian Carcinosarcoma
- Trial name
- NCT01080521
- Testing
- Cognitive Assessment, Quality-of-Life Assessment
- Where
- 182 sites in United States
- Volunteers
- 247 people
- Sponsor
- Gynecologic Oncology Group
Stage II Breast Cancer, Stage III Breast Cancer
Ask Questions (ASQ):Implementation of a Communication Intervention
This clinical trial implements a communication intervention to improve patient-oncologist communication in the outpatient medical oncology setting.
- Conditions
- Stage II Breast Cancer, Stage III Breast Cancer, Stage IV Breast Cancer, Stage II Colorectal Cancer
- Trial name
- NCT05025748
- Testing
- Behavioral Intervention
- Where
- 8 sites in United States
- Volunteers
- 81 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Ovarian Neoplasms, Ovarian Diseases
Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.
This is a single-arm, exploratory study. People with recurrent platinum-resistant ovarian cancer who have not received any previous systemic antitumor therapy for ovarian cancer were selected to evaluate the efficacy and safety…
- Trial name
- NCT05753826
- Testing
- Adebrelimab, Fuzuloparib
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Fujian Cancer Hospital
Cervical Cancer, Endometrial Cancer
Clinical Trial Protocol to Evaluate the Efficacy and Safety of Laparoscopic Surgical Systems for Gynaecological Surgery
Evaluation of the efficacy and safety of thoracic and abdominal endoscopic surgical systems manufactured by Shenzhen Cornerstone Robotics Technology Co., Ltd. for use ingynaecological surgical procedures.
- Trial name
- NCT06598085
- Testing
- Robot-assisted surgery
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Cornerstone Robotics
Precancerous Condition
SGN-00101 in Treating Patients With Cervical Intraepithelial Neoplasia
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of or treat early cancer. SGN-00101 may be effective in preventing the development of cervical cancer in patients with cervical…
- Trial name
- NCT00060099
- Testing
- HspE7
- Where
- United States
- Sponsor
- Dana-Farber/Brigham and Women's Cancer Center
Endometrial Neoplasms
MRI Radiomics Combined With Pathomics on the Prediction of Molecular Classification and Prognosis of Endometrial Cancer
Molecular typing provides accurate information for the diagnosis, treatment and prognosis prediction of endometrial cancer, which has important clinical significance.
- Trial name
- NCT06126393
- Testing
- next generation sequencing AND Immunohistochemical examination
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Fujian Cancer Hospital
Ovarian Cancer
Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer
This study is an open-label, multicenter, umbrella study aimed to evaluate the combined, biomarker-driven, targeted treatment efficiency of Pamiparib, Bevacizumab, Tislelizumab, and Nab-paclitaxel in patients with…
- Trial name
- BRIGHT (NCT05044871)
- Testing
- Pamiparib, Bevacizumab, Tislelizumab
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Tongji Hospital
Ovarian Cancer, Recurrent Ovarian Carcinoma
A New Fast DWI-based MR Protocol for Surveillance in Patients With a High Risk of Ovarian Cancer Recurrence During PARP-inhibitors Maintenance to Enhance Secondary Cytoreduction Results
In ovarian cancer (OC), complete surgical debulking and platinum-based chemotherapy are the standard treatment, now followed by maintenance therapy with PARP inhibitors or Bevacizumab.
- Trial name
- FOFU (NCT06541171)
- Testing
- Magnetic resonance imaging as fpr clinical practice
- Where
- Italy
- Volunteers
- 220 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Cervical Cancer
Community Outreach-based Study to Increase Cervical Cancer Screening Among Hispanic Women in Cleveland
This study offers Hispanic women who are eligible for cervical cancer screening residing in the Cleveland metropolitan area one of two possible community outreach-based cervical cancer screening modalities, self-collection home…
- Trial name
- NCT05470309
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- MetroHealth Medical Center
Epithelial Ovarian Cancer
Health-Economic Evaluation of Early Diagnosis of Epithalial Ovarian Cancer Recurrence Using the ROMA Score: a Prospective Multicenter Randomized Trial
In this study, we hypothesize that calculating the ROMA score (CA125 + HE4 blood marker assay) will enable faster, more targeted diagnosis and management of epithelial ovarian cancer recurrence than the CA125 marker assay alone.
- Trial name
- ROMECO (NCT05991752)
- Testing
- ROMA score evaluation
- Sponsor
- University Hospital, Tours
Malignant Neoplasms of Female Genital Organs, Ovarian Cancer
Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery
The goal of this clinical research study is to learn if Avastin (bevacizumab) can help to control ovarian, fallopian, or primary peritoneal cancer that has been found during second-look surgery.
- Conditions
- Malignant Neoplasms of Female Genital Organs, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT02884648
- Testing
- Bevacizumab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- M.D. Anderson Cancer Center
Radiation-Induced Dermatitis
A Study for Assessing the Efficacy and Safety of Tetrahydrobiopterin in Radiation-Induced Skin Injury
This study was a single-center prospective phase I clinical study to evaluate the effectiveness and safety of BH4 in the treatment of radiation-induced skin injury during vulvar cancer radiotherapy.
- Trial name
- NCT05114226
- Testing
- Tetrahydrobiopterin
- Where
- China
- Volunteers
- 45 people
- Sponsor
- West China Second University Hospital
Cervical Cancer
Using CHWs or Mailing Self Sampling Home Tests to Increase Cervical Cancer Screening in South Florida
The study will test the significance of community health worker (CHW) participation by comparing self-sampling provided by a community health worker and self-sampling provided by mail.
- Trial name
- NCT02202109
- Testing
- CHW and Self-sampling for Cervical Cancer, Mailed Self Sampler
- Where
- United States
- Volunteers
- 602 people
- Sponsor
- University of Miami
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.